Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 5
1978 3
1979 2
1980 7
1981 4
1982 6
1983 6
1984 1
1985 4
1986 2
1987 4
1988 1
1989 2
1990 6
1991 3
1992 2
1993 5
1995 5
1996 3
1997 4
1998 2
1999 14
2000 5
2001 6
2002 5
2003 12
2004 20
2005 8
2006 16
2007 17
2008 22
2009 27
2010 20
2011 15
2012 28
2013 34
2014 22
2015 20
2016 18
2017 17
2018 25
2019 10
2020 12
2021 15
2022 15
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Results by year

Filters applied: . Clear all
The following terms were ignored: "", OR
Page 1
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, del Zoppo GJ, Kumar MA, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL. Frontera JA, et al. Neurocrit Care. 2016 Feb;24(1):6-46. doi: 10.1007/s12028-015-0222-x. Neurocrit Care. 2016. PMID: 26714677 Review.
Pharmaceutical approval update.
Goldenberg MM. Goldenberg MM. P T. 2014 Apr;39(4):262-96. P T. 2014. PMID: 24757362 Free PMC article.
Ibrutinib (Imbruvica) for chronic lymphocytic leukemia, tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder, and anti-inhibitor coagulant complex (Feiba) to prevent or reduce bleeding in hemophilia A or B....
Ibrutinib (Imbruvica) for chronic lymphocytic leukemia, tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder, and anti-inhibi …
FEIBA: mode of action.
Turecek PL, Váradi K, Gritsch H, Schwarz HP. Turecek PL, et al. Haemophilia. 2004 Sep;10 Suppl 2:3-9. doi: 10.1111/j.1365-2516.2004.00934.x. Haemophilia. 2004. PMID: 15385040 Review.
Recently it was shown that FEIBA contains the proenzymes of the prothrombin complex factors, prothrombin, FVII, FIX and FX, but only very small amounts of their activation products, with the exception of FVIIa, which is contained in FEIBA in greater amounts. ...The …
Recently it was shown that FEIBA contains the proenzymes of the prothrombin complex factors, prothrombin, FVII, FIX and FX, but only …
FEIBA: a prohemostatic agent.
Cromwell C, Aledort LM. Cromwell C, et al. Semin Thromb Hemost. 2012 Apr;38(3):265-7. doi: 10.1055/s-0032-1309286. Epub 2012 Mar 29. Semin Thromb Hemost. 2012. PMID: 22460908 Review.
Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac patients with inhibitors. ...The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains....
Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac …
Reversing the anticoagulation effects of dabigatran.
Dager WE, Banares L. Dager WE, et al. Hosp Pract (1995). 2017 Apr;45(2):29-38. doi: 10.1080/21548331.2017.1298389. Epub 2017 Mar 24. Hosp Pract (1995). 2017. PMID: 28335637 Review.
Other nonspecific agents, including recombinant activated factor VII, three- and four-factor prothrombin complex concentrates (PCC), and activated PCC or Factor Eight Inhibitor Bypassing Activity (FEIBA), are options based on clinical need. Specific agents to quickly rever …
Other nonspecific agents, including recombinant activated factor VII, three- and four-factor prothrombin complex concentrates (PCC), and act …
Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies.
Ibarra F Jr, Cruz M, Ford M, Wu MJ. Ibarra F Jr, et al. Pharmacy (Basel). 2022 Apr 23;10(3):50. doi: 10.3390/pharmacy10030050. Pharmacy (Basel). 2022. PMID: 35645329 Free PMC article.
The primary outcome was the percentage of patients who had a post-FEIBA INR 1.5. In the total population, 55.6% (10/18) of patients achieved a post-FEIBA INR 1.5. In the subgroup analysis, significantly more patients in the low dose FEIBA group achieved a pos …
The primary outcome was the percentage of patients who had a post-FEIBA INR 1.5. In the total population, 55.6% (10/18) of patients a …
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
Ettingshausen CE, Hermans C, Holme PA, Cid AR, Khair K, Oldenburg J, Négrier C, Botha J, Lelli A, Windyga J. Ettingshausen CE, et al. Ther Adv Hematol. 2023 Jul 24;14:20406207231184323. doi: 10.1177/20406207231184323. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37529276 Free PMC article.
BACKGROUND: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative management, and routin …
BACKGROUND: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxa …
FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hemophilie A acquise' (FEIBHAC) registry.
Borg JY, Négrier C, Durieu I, Dolimier E, Masquelier AM, Lévesque H; FEIBHAC Study Group. Borg JY, et al. Haemophilia. 2015 May;21(3):330-337. doi: 10.1111/hae.12574. Epub 2014 Oct 31. Haemophilia. 2015. PMID: 25359571
Due to the low incidence of AHA, available clinical data on FEIBA treatment are limited. The study aim was to delineate practice patterns in FEIBA treatment of AHA patients, the haemostatic efficacy of FEIBA, including criteria for its assessment, and safety. …
Due to the low incidence of AHA, available clinical data on FEIBA treatment are limited. The study aim was to delineate practice patt …
Acquired haemophilia syndrome: pathophysiology and therapy.
Elezović I. Elezović I. Srp Arh Celok Lek. 2010 Jan;138 Suppl 1:64-8. doi: 10.2298/sarh10s1064e. Srp Arh Celok Lek. 2010. PMID: 20229686 Free article. Review.
Two options are currently available for acute bleeding control: the use rFVIIa or FEIBA in patients with higher inhibitor titer (> 5 BU), or to raise the level of FVIII by administration of DDAVP or concentrates of FVIII in patients with low level of inhibitors (< 5 …
Two options are currently available for acute bleeding control: the use rFVIIa or FEIBA in patients with higher inhibitor titer (> …
434 results